Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
989
datasets available to search
ShareScore release 0.9.0
Dataset results
989 results for “Myelodysplastic syndrome”
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
ClinicalTrials.gov study NCT00940602. IPD Sharing: YES. Countries: 16. Publications: 1.
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or L
ClinicalTrials.gov study NCT03268954. IPD Sharing: YES. Countries: 20. Publications: 1.
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML
ClinicalTrials.gov study NCT02610777. IPD Sharing: YES. Countries: 12. Publications: 1.
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or
ClinicalTrials.gov study NCT00946647. IPD Sharing: YES. Countries: 14. Publications: 1.
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leu
ClinicalTrials.gov study NCT04266301. IPD Sharing: YES. Countries: 36. Publications: 1.
A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
ClinicalTrials.gov study NCT03946670. IPD Sharing: YES. Countries: 17. Publications: 1.
First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome
ClinicalTrials.gov study NCT03594955. IPD Sharing: YES. Countries: 2. Publications: 1.
Datasets corresponding to publication: Machine learning assisted Real-time deformability cytometry of CD34+ cells allows to identify patients with Myelodysplastic Syndromes
<p>This repository contains all dataset that correspond to the publication "Machine learning assisted Real-time deformability cytometry of CD34+ cells allows to identify patients with Myelodysplastic Syndromes". Furthermore, Python scripts are provided which allow to reproduce all analyses shown in the manuscript. Execution of the scripts requires a Python environment with packages as stated in the Methods section of the manuscript, or by using PyBox 0.1.0. PyBox is a readily installed Python environment containing all packages at the required version. PyBox is publicly available on GitHub: <a href="https://github.com/maikherbig/PyBox">https://github.com/maikherbig/PyBox</a>.</p>
Metabolomics data: glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes
<p>Malignancies can become reliant on glutamine as an alternative energy source and as a facilitator of aberrant DNA methylation, thus implicating glutaminase (GLS) as a potential therapeutic target. We demonstrate preclinical synergy of Telaglenastat (CB-839), a selective GLS inhibitor, when combined with AZA, <em>in vitro</em> and <em>in vivo</em>, followed by a phase Ib/II study of the combination in patients with advanced MDS. Treatment with Telaglenastat/AZA led to an ORR of 70% with CRs in 66% patients and a median overall survival of 11.6 months. scRNAseq and flow cytometry demonstrated a myeloid differentiation program at the stem cell level in clinical responders. Expression of non-canonical glutamine transporter, SLC38A1, was found to be overexpressed in MDS stem cells and was associated with clinical responses to Telaglenastat/AZA; was predictive of worse prognosis in a large MDS cohort. These data demonstrate the safety and efficacy of a combined metabolic and epigenetic approach in MDS.</p>
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
ClinicalTrials.gov study NCT04797780. IPD Sharing: NO. Countries: 13. Publications: 2.
Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
ClinicalTrials.gov study NCT01687400. IPD Sharing: NO. Countries: 1. Publications: 1.
An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)
ClinicalTrials.gov study NCT01186939. IPD Sharing: Not stated. Countries: 11. Publications: 16.
Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes
ClinicalTrials.gov study NCT02131597. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
ClinicalTrials.gov study NCT00398138. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)
ClinicalTrials.gov study NCT01339910. IPD Sharing: YES. Countries: 1. Publications: 5.
Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden
ClinicalTrials.gov study NCT03263091. IPD Sharing: NO. Countries: 16. Publications: 1.
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
ClinicalTrials.gov study NCT02521493. IPD Sharing: Not stated. Countries: 6. Publications: 1.
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
ClinicalTrials.gov study NCT01898793. IPD Sharing: NO. Countries: 1. Publications: 4.
Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia
ClinicalTrials.gov study NCT03019939. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
ClinicalTrials.gov study NCT01289457. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.